Department of Otorhinolaryngology - Head and Neck Surgery, Sengkang General Hospital, SingHealth, Singapore, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
J Laryngol Otol. 2023 Dec;137(12):1300-1311. doi: 10.1017/S0022215123000543. Epub 2023 Mar 31.
This review evaluated the safety profile and efficacy of probiotics in chronic rhinosinusitis and was registered with Prospero (Centre for Reviews and Dissemination number: 42020193529).
Literature databases were searched through inception to August 2022. Randomised, controlled trials exploring adjunctive probiotics in adult chronic rhinosinusitis patients were included. From 948 records screened, 4 randomised, controlled trials were included.
Probiotics-associated adverse effects comprised epistaxis and abdominal pain. No reduction in Sino-Nasal Outcome Test values before 4 weeks ( 0.58) or beyond 8 weeks ( 0.08) of treatment or reduction of severe symptom frequency ( 0.75) was observed. Symptom relapse in probiotic-treated patients was significantly lower across all timepoints ( 0.045). Lower sinusitis relapse risks during treatment (risk ratio = 0.49; 0.019) and 8 months post-treatment (risk ratio = 0.56, 0.013) were observed. Probiotics demonstrated potential in improving Sino-Nasal Outcome Test symptom subscales, including sleep, psychological and rhinology subscales.
The optimal mode of probiotic administration, treatment duration and target patient subgroups requires further study to evaluate the utility of probiotics.
本综述评估了益生菌在慢性鼻-鼻窦炎中的安全性和疗效，并在 PROSPERO（中心审查和传播编号：42020193529）上进行了注册。
从成立到 2022 年 8 月，对文献数据库进行了检索。纳入了探索益生菌辅助治疗成人慢性鼻-鼻窦炎患者的随机对照试验。从筛选出的 948 条记录中，纳入了 4 项随机对照试验。
益生菌相关的不良反应包括鼻出血和腹痛。治疗前 4 周（ 0.58）或 8 周后（ 0.08），Sino-Nasal Outcome Test 值没有降低，严重症状频率也没有降低（ 0.75）。在所有时间点，益生菌治疗患者的症状复发率明显较低（ 0.045）。在治疗期间（风险比=0.49； 0.019）和治疗后 8 个月（风险比=0.56， 0.013），鼻窦炎症复发的风险较低。益生菌在改善 Sino-Nasal Outcome Test 症状子量表方面显示出一定的潜力，包括睡眠、心理和鼻科学子量表。
需要进一步研究益生菌的最佳给药方式、治疗持续时间和目标患者亚组，以评估益生菌的效用。
